Fate Therapeutics Inc (FATE)

EBITDA Growth

9.80%

Quarterly · Period ending:

FATE logo

FATE EBITDA Growth

Year-over-year change vs the same period a year earlier

Latest reported9.80%
FATE Quarterly EBITDA YoY % (-43.21% → 9.80%)
High-resolution chart · PNG

FATE ebitda growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Fate Therapeutics Inc EBITDA Growth — Quarterly
Period endingEBITDA Growth
9.8012%
17.4784%
30.5394%
32.6159%
8.6453%
20.5984%
-7.5464%
-6.5323%
30.1994%
-193.9619%
23.8427%
49.6952%
33.98%
76.6562%
22.4257%
-92.3233%
-35.5328%
-39.0665%
-104.1152%
-36.0585%
-93.0219%
-33.9302%
-19.885%
-19.8735%
-24.1188%
-78.6254%
-77.7407%
-59.7083%
-18.8833%
-40.768%
-29.4616%
-59.4415%
-105.9118%
-39.1858%
-59.2198%
-23.703%
-18.4146%
-25.556%
-10.5342%
-32.454%
-10.1332%
-6.851%
-15.1942%
-4.6345%
-19.4515%
-5.6061%
-21.894%
-17.1925%
-11.4318%
-107.0495%
-22.8888%
-43.2085%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.